I
Ira Braunschweig
Researcher at Albert Einstein College of Medicine
Publications - 104
Citations - 5933
Ira Braunschweig is an academic researcher from Albert Einstein College of Medicine. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 17, co-authored 75 publications receiving 3671 citations. Previous affiliations of Ira Braunschweig include Yeshiva University & Montefiore Medical Center.
Papers
More filters
Journal ArticleDOI
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
Sattva S. Neelapu,Frederick L. Locke,Nancy L. Bartlett,Lazaros J. Lekakis,David B. Miklos,Caron A. Jacobson,Ira Braunschweig,Olalekan O. Oluwole,Tanya Siddiqi,Yi Lin,John M. Timmerman,Patrick J. Stiff,Jonathan W. Friedberg,Ian W. Flinn,Andre Goy,Brian T. Hill,Mitchell R. Smith,Abhinav Deol,Umar Farooq,Peter A. McSweeney,Javier Munoz,Irit Avivi,Januario E. Castro,Jason R. Westin,Julio C. Chavez,Armin Ghobadi,Krishna V. Komanduri,Ronald Levy,Eric D. Jacobsen,Thomas E. Witzig,Patrick M. Reagan,Adrian Bot,John J. Rossi,Lynn Navale,Yizhou Jiang,Jeff Aycock,Meg Elias,David Z. Chang,Jeff Wiezorek,William Y. Go +39 more
TL;DR: Patients with refractory large B‐cell lymphoma who received CAR T‐cell therapy with axi‐cel had high levels of durable response, with a safety profile that included myelosuppression, the cytokine release syndrome, and neurologic events.
Journal ArticleDOI
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial
Frederick L. Locke,Armin Ghobadi,Caron A. Jacobson,David B. Miklos,Lazaros J. Lekakis,Olalekan O. Oluwole,Yi Lin,Ira Braunschweig,Brian T. Hill,John M. Timmerman,Abhinav Deol,Patrick M. Reagan,Patrick J. Stiff,Ian W. Flinn,Umar Farooq,Andre Goy,Peter A. McSweeney,Javier Munoz,Tanya Siddiqi,Julio C. Chavez,Alex F. Herrera,Nancy L. Bartlett,Jeffrey S. Wiezorek,Lynn Navale,Allen Xue,Yizhou Jiang,Adrian Bot,John M. Rossi,Jenny J. Kim,William Y. Go,Sattva S. Neelapu +30 more
TL;DR: Long-term activity and safety outcomes of the ZUMA-1 study suggest that axicabtagene ciloleucel can induce durable responses and a median overall survival of greater than 2 years, and has a manageable relapsed or refractory disease or relapsed after autologous stem-cell transplantation.
Journal ArticleDOI
Genomewide DNA methylation analysis reveals novel targets for drug development in mantle cell lymphoma
Violetta V. Leshchenko,Pei-Yu Kuo,Rita Shaknovich,David T. Yang,Tobias A. Gellen,Adam M. Petrich,Yiting Yu,Yvonne Remache,Marc A. Weniger,Sarwish Rafiq,K. Stephen Suh,Andre Goy,Wyndham H. Wilson,Amit Verma,Ira Braunschweig,Natarajan Muthusamy,Brad S. Kahl,John C. Byrd,Adrian Wiestner,Ari Melnick,Samir Parekh +20 more
TL;DR: The data show prominent and aberrant promoter methylation in MCL and suggest that differentially methylated genes can be targeted for therapeutic benefit in M CL.
Journal ArticleDOI
Axicabtagene ciloleucel CD19 CAR-T cell therapy results in high rates of systemic and neurologic remissions in ten patients with refractory large B cell lymphoma including two with HIV and viral hepatitis.
Ahmed Abbasi,Stephen Peeke,Nishi Shah,Jennat Mustafa,Fariha Khatun,Amanda Lombardo,Michelly Abreu,Richard Elkind,Karen Fehn,Alyssa De Castro,Yanhua Wang,Olga Derman,Randin Nelson,Joan Uehlinger,Kira Gritsman,R. Alejandro Sica,Noah Kornblum,Ioannis Mantzaris,Aditi Shastri,Murali Janakiram,Mendel Goldfinger,Amit Verma,Ira Braunschweig,Lizamarie Bachier-Rodriguez +23 more
TL;DR: Axi-cel led to significant efficacy with manageable toxicity in DLBCL in a real-world setting and was generally well tolerated with 20% of patients experiencing grade ≥ 2 CRS.
Journal ArticleDOI
Preliminary Results of Prophylactic Tocilizumab after Axicabtageneciloleucel (axi-cel; KTE-C19) Treatment for Patients with Refractory,Aggressive Non-Hodgkin Lymphoma (NHL)
Frederick L. Locke,Sattva S. Neelapu,Nancy L. Bartlett,Lazaros J. Lekakis,Caron A. Jacobson,Ira Braunschweig,Olalekan O. Oluwole,Tanya Siddiqi,Yi Lin,John M. Timmerman,Patrick M. Reagan,Adrian Bot,John M. Rossi,Marika Sherman,Lynn Navale,Yizhou Jiang,Jeff Aycock,Meg Elias,Jeffrey S. Wiezorek,William Y. Go,David B. Miklos +20 more
TL;DR: Early use of tocilizumab may reduce the incidence of severe CRS but not NE in patients treated with CAR T cell therapy, and data provide evidence that the underlying pathophysiology of NE may differ from that of CRS.